Literature DB >> 27837030

Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Arvind Arora1,2, Swetha Parvathaneni3, Mohammed A Aleskandarany4, Devika Agarwal5, Reem Ali1, Tarek Abdel-Fatah2, Andrew R Green4, Graham R Ball5, Emad A Rakha4, Ian O Ellis4, Sudha Sharma6, Srinivasan Madhusudan7,2.   

Abstract

RECQL1, a key member of the RecQ family of DNA helicases, is required for DNA replication and DNA repair. Two recent studies have shown that germline RECQL1 mutations are associated with increased breast cancer susceptibility. Whether altered RECQL1 expression has clinicopathologic significance in sporadic breast cancers is unknown. We evaluated RECQL1 at the transcriptomic level (METABRIC cohort, n = 1,977) and at the protein level [cohort 1, n = 897; cohort 2, n = 252; cohort 3 (BRCA germline deficient), n = 74]. In RECQL1-depleted breast cancer cells, we investigated anthracycline sensitivity. High RECQL1 mRNA was associated with intClust.3 (P = 0.026), which is characterized by low genomic instability. On the other hand, low RECQL1 mRNA was linked to intClust.8 [luminal A estrogen receptor-positive (ER+) subgroup; P = 0.0455] and intClust.9 (luminal B ER+ subgroup; P = 0.0346) molecular phenotypes. Low RECQL1 expression was associated with shorter breast cancer-specific survival (P = 0.001). At the protein level, low nuclear RECQL1 level was associated with larger tumor size, lymph node positivity, high tumor grade, high mitotic index, pleomorphism, dedifferentiation, ER negativity, and HER-2 overexpression (P < 0.05). In ER+ tumors that received endocrine therapy, low RECQL1 was associated with poor survival (P = 0.008). However, in ER- tumors that received anthracycline-based chemotherapy, high RECQL1 was associated with poor survival (P = 0.048). In RECQL1-depleted breast cancer cell lines, we confirmed doxorubicin sensitivity, which was associated with DNA double-strand breaks accumulation, S-phase cell-cycle arrest, and apoptosis. We conclude that RECQL1 has prognostic and predictive significance in breast cancers. Mol Cancer Ther; 16(1); 239-50. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27837030      PMCID: PMC5222686          DOI: 10.1158/1535-7163.MCT-16-0290

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  43 in total

1.  The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Authors:  Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs
Journal:  Oncologist       Date:  2011-10-20

2.  Germline RECQL mutations are associated with breast cancer susceptibility.

Authors:  Cezary Cybulski; Jian Carrot-Zhang; Wojciech Kluźniak; Barbara Rivera; Aniruddh Kashyap; Dominika Wokołorczyk; Sylvie Giroux; Javad Nadaf; Nancy Hamel; Shiyu Zhang; Tomasz Huzarski; Jacek Gronwald; Tomasz Byrski; Marek Szwiec; Anna Jakubowska; Helena Rudnicka; Marcin Lener; Bartłomiej Masojć; Patrica N Tonin; Francois Rousseau; Bohdan Górski; Tadeusz Dębniak; Jacek Majewski; Jan Lubiński; William D Foulkes; Steven A Narod; Mohammad R Akbari
Journal:  Nat Genet       Date:  2015-04-27       Impact factor: 38.330

Review 3.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  RECQL4 helicase has oncogenic potential in sporadic breast cancers.

Authors:  Arvind Arora; Devika Agarwal; Tarek Ma Abdel-Fatah; Huiming Lu; Deborah L Croteau; Paul Moseley; Mohammed A Aleskandarany; Andrew R Green; Graham Ball; Emad A Rakha; Stephen Yt Chan; Ian O Ellis; Lisa L Wang; Yongliang Zhao; Adayabalam S Balajee; Vilhelm A Bohr; Srinivasan Madhusudan
Journal:  J Pathol       Date:  2016-02-02       Impact factor: 7.996

5.  RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.

Authors:  Kazunobu Futami; Sachiko Ogasawara; Hideyuki Goto; Hirohisa Yano; Yasuhiro Furuichi
Journal:  Int J Mol Med       Date:  2010-04       Impact factor: 4.101

6.  RECQL, a member of the RecQ family of DNA helicases, suppresses chromosomal instability.

Authors:  Sudha Sharma; Deborah J Stumpo; Adayabalam S Balajee; Cheryl B Bock; Peter M Lansdorp; Robert M Brosh; Perry J Blackshear
Journal:  Mol Cell Biol       Date:  2006-12-11       Impact factor: 4.272

7.  Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

Authors:  Arvind Arora; Tarek M A Abdel-Fatah; Devika Agarwal; Rachel Doherty; Deborah L Croteau; Paul M Moseley; Khalid Hameed; Andrew Green; Mohammed A Aleskandarany; Emad A Rakha; Karl Patterson; Graham Ball; Stephen Y T Chan; Ian O Ellis; Vilhelm A Bohr; Helen E Bryant; Srinivasan Madhusudan
Journal:  Carcinogenesis       Date:  2015-11-19       Impact factor: 4.944

8.  Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.

Authors:  Ping Zhang; Zhiyuan Zhang; Xiaojian Zhou; Weiliu Qiu; Fangan Chen; Wantao Chen
Journal:  BMC Cancer       Date:  2006-09-15       Impact factor: 4.430

Review 9.  Probing Genome Maintenance Functions of human RECQ1.

Authors:  Furqan Sami; Sudha Sharma
Journal:  Comput Struct Biotechnol J       Date:  2013-10-18       Impact factor: 7.271

10.  An appraisal of RECQ1 expression in cancer progression.

Authors:  Sudha Sharma
Journal:  Front Genet       Date:  2014-12-05       Impact factor: 4.599

View more
  9 in total

1.  The DNA repair helicase RECQ1 has a checkpoint-dependent role in mediating DNA damage responses induced by gemcitabine.

Authors:  Swetha Parvathaneni; Sudha Sharma
Journal:  J Biol Chem       Date:  2019-08-23       Impact factor: 5.157

2.  Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.

Authors:  Huiying Xu; Ye Xu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  BMC Cancer       Date:  2018-06-18       Impact factor: 4.430

3.  Transcriptional regulation by a RecQ helicase.

Authors:  Subrata Debnath; Xing Lu; Sudha Sharma
Journal:  Methods Enzymol       Date:  2022-04-18       Impact factor: 1.682

4.  Genome-wide investigations on regulatory functions of RECQ1 helicase.

Authors:  Subrata Debnath; Xing Lu; Ashish Lal; Sudha Sharma
Journal:  Methods       Date:  2022-02-26       Impact factor: 4.647

5.  High Expression of RECQL Protein in ER-Positive Breast Tumours Is Associated With a Better Survival.

Authors:  Ardalan Mahmoodi; Ahmed Shoqafi; Ping Sun; Vasily Giannakeas; Cezary Cybulski; Sharon Nofech-Mozes; Jean-Yves Masson; Sudha Sharma; Amir Abbas Samani; Srinivasan Madhusudan; Steven A Narod; Mohammad R Akbari
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

6.  Distinct prognosis of mRNA expression of the five RecQ DNA-helicase family members - RECQL, BLM, WRN, RECQL4, and RECQL5 - in patients with breast cancer.

Authors:  Xuan Zhu; Huihui Chen; Yi Yang; Chunjing Xu; Jun Zhou; Jiaojiao Zhou; Yiding Chen
Journal:  Cancer Manag Res       Date:  2018-12-05       Impact factor: 3.989

7.  RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner.

Authors:  Swetha Parvathaneni; Xing Lu; Ritu Chaudhary; Ashish Lal; Srinivasan Madhusudan; Sudha Sharma
Journal:  Oncotarget       Date:  2017-05-27

8.  The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.

Authors:  Giancarlo Barone; Arvind Arora; Anil Ganesh; Tarek Abdel-Fatah; Paul Moseley; Reem Ali; Stephen Yt Chan; Constantinos Savva; Kristina Schiavone; Natasha Carmell; Katie N Myers; Emad A Rakha; Srinivasan Madhusudan; Spencer J Collis
Journal:  Oncotarget       Date:  2018-06-29

Review 9.  RECQ1 Helicase in Genomic Stability and Cancer.

Authors:  Subrata Debnath; Sudha Sharma
Journal:  Genes (Basel)       Date:  2020-06-05       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.